This site uses cookies. By using this site you agree to receiving cookies. View Policy.

129%

Callaly is the UK’s first femcare B-Corp and was described by The Independent as “revolutionising the multi-billion pound feminine care industry”. Delivering organic cotton period products via subscription, Callaly invented & patented the tampliner – the first significant tampon innovation in 80+ years.

  • £26bn global femcare market – our potential tampliner market is estimated at 2%-4% by 2024 
  • Fast subscriber growth >160% between March and May ’20
  • Our 4 patents cover 80% of the market; Deloitte valued it at £90m
  • £7.9m angel & Innovate UK funding to date; bespoke machinery developed

Idea

Callaly is using groundbreaking innovation to transform the £26bn femcare industry. As well as inventing the tampliner, a multi-patented period product that solves the problems of traditional tampons, it offers a range of organic cotton period products in customisable mixes, by home delivery.

Callaly has won several industry awards & is rated 4.85/5 by customers. The tampliner was described by Cosmo as a “game changer” and by Grazia as “genius”.

The tampliner was invented by gynaecologist Dr Alex Hooi, who had heard 35 years of women’s frustrations with femcare products. Many complained of discomfort, inconvenience and leaks. Research found 7 out of 10 women who use tampons also add a liner in case of leaks – an expensive and wasteful solution.

The tampliner combines an organic cotton tampon with a soft mini-liner for built-in leak protection, with unique clean insertion and removal, and no hard plastic applicator.

Alex was joined by garment technologist Ewa and former private equity investor Thang to turn the invention into a flourishing business. The tampliner is multi-patented in 30 countries (with potential for IVF/medicine delivery) and Callaly has developed bespoke robotic machinery to automate production at a UK facility. After the UK full launch in Q1 ’20,Callaly plans to begin European sales in Q3 ’20, followed by the US & Asia in ’21 (with expected regulatory approval).

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

To see the rest of the Callaly pitch, join now. It's free, quick and easy.

Due to financial regulations, you need to join our community to view the full investment opportunity.

Join

Already registered? Log in

This pitch is approved by Crowdcube

This pitch is approved as a financial promotion by Crowdcube Capital Limited. Every pitch on Crowdcube is reviewed to ensure it is fair, clear and not misleading.

As part of our commitment to investor transparency, Crowdcube’s Due Diligence Charter outlines the analysis and verification that is conducted on equity fundraises on Crowdcube by our legal and compliance professionals.

Read more

Risk warning

Investments of this nature carry risks to your capital, including illiquidity, lack of dividends and dilution. Balance risk with a diversified portfolio. Read more. Approved as a financial promotion by Crowdcube Capital Limited, which is authorised and regulated by the Financial Conduct Authority.

Investment opportunities are not offers to the public and investors must be eligible Crowdcube members. Further restrictions and Crowdcube's limitation of liability are set out in the Investor Terms and Conditions. Please seek independent advice as required as Crowdcube does not give investment or tax advice.

Callaly has been given advance assurance by HMRC that the proposed share issue is likely to qualify for Enterprise Investment Scheme (EIS) tax relief.

Tax relief is available to individuals only, with income tax relief currently set at 30 per cent of the cost of the shares for the tax year in which the investment was made. The tax reliefs can also reduce your Capital Gains Tax bill. Read More.

Availability of tax relief depends on your individual and the company’s ongoing circumstances and applicable law.